Skip to main content

Month: July 2025

Ponce Financial Group, Inc. Reports Second Quarter 2025 Results

NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) — Ponce Financial Group, Inc., (the “Company”) (NASDAQ: PDLB), the holding company for Ponce Bank (the “Bank”), today announced results for the second quarter of 2025. Second Quarter 2025 Highlights (Compared to Prior Periods):Net income available to common stockholders was $5.8 million, or $0.25 per diluted share for the three months ended June 30, 2025, as compared to net income available to common stockholders of $5.7 million, or $0.25 per diluted share for the three months ended March 31, 2025, and net income available to common stockholders of $3.1 million, or $0.14 per diluted share for the three months ended June 30, 2024. Total net income for the three months ended June 30, 2025, was $6.1 million. The Company paid dividends of $0.3 million on its preferred stock during the three...

Continue reading

Postal Realty Trust, Inc. to Report Second Quarter 2025 Financial Results on August 4, 2025

CEDARHURST, N.Y., July 25, 2025 (GLOBE NEWSWIRE) — Postal Realty Trust, Inc. (NYSE: PSTL) (the “Company”), an internally managed real estate investment trust that owns and manages over 2,150 properties leased primarily to the United States Postal Service (the “USPS”), ranging from last-mile post offices to industrial facilities, announced today that it will report its financial results for the period ended June 30, 2025, on Monday, August 4, 2025, after market close. Webcast and Call Information: The Company will host a webcast and conference call to discuss the second quarter 2025 financial results on Tuesday, August 5, 2025, at 9:00 A.M. Eastern Time. A live audio webcast of the conference call will be available on the Company’s investor website at https://investor.postalrealtytrust.com/Investors/events-and-presentations/default.aspx....

Continue reading

Colliers completes acquisition of Astris Finance

TORONTO and WASHINGTON, D.C., July 25, 2025 (GLOBE NEWSWIRE) — Global diversified professional services and investment management company, Colliers (NASDAQ, TSX: CIGI), announced today it has completed its previously announced acquisition of a controlling interest in Astris Infrastructure, LLC (“Astris Finance”), a global investment banking firm specializing in infrastructure and energy transition. The acquisition significantly expands Colliers’ investment banking capabilities and capitalizes on the growing global demand for infrastructure that supports urbanization, energy security, and decarbonization. Colliers Contact Christian MayerChief Financial Officer+1 416 960 9500 About Colliers Colliers (NASDAQ, TSX: CIGI) is a global diversified professional services and investment management company. Operating through three industry-leading...

Continue reading

Pampa Metals and Rugby Resources Complete Arrangement Transaction

(CSE: PM) (FSE: FIR) (OTCQB: PMMCF)        For Immediate Release Vancouver, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — Pampa Metals Corporation (“Pampa Metals”) (CSE:PM / FSE:FIR / OTCQB:PMMCF) and Rugby Resources Ltd. (“Rugby”) (TSXV:RUG) are pleased to announce completion of the acquisition of all the issued and outstanding common shares of Rugby (the “Rugby Shares”) by Pampa Metals (refer April 22, 2025 News Release). Under the terms of the court approved arrangement (the “Arrangement”), 65,165,185 common shares of Pampa Metals (the “Pampa Shares”) are being issued in connection with closing to former Rugby shareholders on the basis of one Pampa Share for every 6.4 Rugby Shares. In connection with the Arrangement, Bryce Roxburgh, outgoing President and CEO, of Rugby has been appointed to the board of directors of Pampa...

Continue reading

BriaCell Announces Two Clinical Data Poster Presentations at ESMO 2025

PHILADELPHIA and VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces two clinical data poster presentations at the European Society for Medical Oncology (ESMO) Congress 2025 Annual Meeting taking place October 17 – 21 in Berlin, Germany. The titles of the poster presentations are listed below. #8212: Phase III Pivotal Trial of Bria-IMT + CPI vs Physician’s Choice in Advanced Metastatic Breast Cancer (BRIA-ABC) #3928: Feasibility and Biomarker Validation of an International Randomized Phase 3 Trial of Bria-IMT Cell Therapy in Late Stage MBC (BRIA-ABC) Abstracts will be published online via the ESMO website at 00:05...

Continue reading

Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo

NEW YORK and MELBOURNE, Australia, July 25, 2025 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing combination drug therapies for high-impact indications, announces the appointment of Charlene E. Gamaldo, M.D. to its IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board. Incannex Chief Medical Officer Dr. Lou Barbato commented:“We are fortunate to welcome Dr. Gamaldo to the Incannex Clinical Advisory Board. Her leadership across neurology, psychiatry, and public health, combined with a distinguished track record in sleep medicine, brings tremendous value to our obstructive sleep apnea program. With the highly anticipated Phase 2 data readout for IHL-42X expected next week, Dr. Gamaldo’s appointment reflects our growing confidence...

Continue reading

Bombardier Delivers the First Challenger 3500 Business Jet in Costa Rica

The delivery underscores the growing presence and global success of Bombardier in Central America The Challenger 3500 is ideally suited for the Central American market, offering the perfect balance of range, efficiency, and versatility to connect key regional citiesMONTRÉAL, July 25, 2025 (GLOBE NEWSWIRE) — Bombardier today announced the delivery of its first Challenger 3500 business jet in Costa Rica, marking a significant milestone for the company in Central America. With a platform that has consistently led the super-midsize segment for over two decades, the Challenger 3500 aircraft offers the ultimate combination of performance, comfort and reliability to customers around the world. “With its high reliability, modern cabin and exceptional runway performance, the Challenger 3500 has quickly established itself as the aircraft...

Continue reading

Form 8.3 – [MARLOWE PLC – 24 07 2025] – (CGWL)

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED (for Discretionary clients)(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree MARLOWE PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing...

Continue reading

ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression

CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specifically indicated to treat depressive symptoms for women with PPD. ZURZUVAE is a once-daily, oral, 14-day treatment which was approved by the U.S. Food and Drug Administration (FDA) in 2023. “This is an important milestone for maternal health in the European Union,” said Priya Singhal, M.D., M.P.H., Head of Development at Biogen. “ZURZUVAE represents a novel...

Continue reading

Valeura Energy Inc.: Strategic Farm-in Agreement with PTTEP

Major Offshore Acreage Expansion Creates New Growth Platform in the Gulf of ThailandSINGAPORE, July 25, 2025 (GLOBE NEWSWIRE) — Valeura Energy Inc. (TSX:VLE, OTCQX:VLERF) (“Valeura” or the “Company”) is pleased to announce that it has entered into a Farm-in Agreement with PTT Exploration and Production Plc (“PTTEP”), through its subsidiary, PTTEP Energy Development Company Limited to earn a 40% interest in Blocks G1/65 and G3/65 (the “Blocks”), in the offshore Gulf of Thailand (the “Farm-in”).  Key HighlightsStrategic Partnership: Farm-in Agreement with PTTEP, the largest oil and gas explorer, producer, and operator in Thailand; Substantial Acreage Expansion: Increases Valeura’s gross acreage position in Thailand from 2,623 km² to 22,757 km²; Prime Location Adjacent...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.